As part of the rationale for the PACIFIC trial, preclinical evidence has suggested that chemotherapy and radiotherapy might upregulate PD-L1 expression on tumor cells and prime T cells, thus it was hypothesized that durvalumab initiation should not be delayed after CRT to provide maximal clinical benefit [11,24,25,26,27]. This evidence concerns the gene CD274 and neoplasm.